Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Cell Therapeutics Inc. Stories

2013-06-27 04:20:59

SEATTLE, June 27, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced results from its Annual Meeting of Shareholders held on Wednesday, June 26, 2013. At the Annual Meeting, shareholders elected John H. Bauer, Phillip M. Nudelman, Ph.D., and Reed V. Tuckson, M.D. to serve on the Company's Board of Directors until the Company's 2016 Annual Meeting. Shareholders approved an amendment to the Company's amended and restated articles of...

2013-06-25 04:21:15

SEATTLE, June 25, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today issued the following statement regarding the notification of the U.S. Food and Drug Administration (the "FDA") partial clinical hold on tosedostat (IND 075503), the Company's aminopeptidase inhibitor under development for the treatment of blood-related cancers, that is being studied in an investigator-sponsored trial and not by CTI. CTI's primary development programs are the ongoing...

2013-06-17 04:22:47

- Pooled Analysis from Four Phase 1 and Phase 2 Clinical Studies Demonstrates Persistence of Treatment - SEATTLE, June 17, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced results from a pooled analysis of data from completed Phase 1 and 2 studies of pacritinib, an oral JAK2/FLT3 inhibitor, demonstrating the safety and tolerability profile of pacritinib in patients with myelofibrosis. An integrated safety analysis of four completed Phase 1...

2013-06-17 00:21:17

- Results Presented at 18th Congress of the European Hematology Association - SEATTLE, June 17, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced results from sub-set analyses of data from the Phase 3 EXTEND, or PIX301, clinical trial of PIXUVRI(®) (pixantrone). The analyses evaluated the efficacy of PIXUVRI in the subset of patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), as confirmed by central...

2013-06-17 00:21:14

SEATTLE, June 17, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTIC and MTA: CTIC) announced today that it is set to join the broad-market Russell 3000® and Russell Global Indexes when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 28, 2013, according to a preliminary list of additions posted on June 14, 2013 and available at www.russell.com/indexes. Annual reconstitution of Russell's U.S. indexes captures the...

2013-06-11 04:22:15

SEATTLE, June 11, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the upcoming presentation of data highlighting PIXUVRI(®) (pixantrone), the first approved treatment in the European Union for aggressive B-cell non-Hodgkin lymphoma (NHL) for adult patients who have failed 2 to 3 prior lines of therapy, and results from a pooled analysis of data from completed Phase 1 and 2 studies of pacritinib, a novel, oral JAK2/FLT3 inhibitor, at the 18(th)...

2013-06-01 08:21:28

CHICAGO and SEATTLE, June 1, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported on final results from a cooperative group and NCI-sponsored Phase 2 clinical trial of brostallicin in combination with cisplatin for the treatment of women with metastatic triple-negative breast cancer (mTNBC). Triple-negative breast cancer lacks progesterone and estrogen receptors and the HER2 biomarker that is present in most breast cancers, which makes standard therapy with...

2013-05-20 04:20:42

- Pricing Negotiations to Begin in June - SEATTLE, May 20, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that Germany's Federal Joint Committee (G-BA) has issued its final benefit assessment report for PIXUVRI® (pixantrone), which is indicated as a monotherapy for the treatment of adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed two or three prior lines of therapy. The G-BA reported that additional...

2013-05-15 04:21:09

SEATTLE, May 15, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that management will present at the following upcoming investor conferences. UBS Global Healthcare ConferenceTuesday, May 21, 2013 at 2:30 p.m. Eastern Time in New York, NY Jefferies 2013 Global Healthcare ConferenceTuesday, June 4, 2013 at 3:00 p.m. Eastern Time in New York, NY The presentations will also be webcast live and available for replay after the...

2013-05-02 16:28:43

- Conference call scheduled today at 4:30 p.m. Eastern time - SEATTLE, May 2, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2013. "In the first quarter, we generated initial commercial sales of PIXUVRI(®) in countries in the European Union where there is market access pending the completion of the reimbursement process," said James Bianco, M.D., President and CEO of CTI....